Boston Scientific (BSX) closed at $78.02 in the latest trading session, marking a +0.42% move from the prior day. This move outpaced the S&P 500's daily gain of 0.28%. On the other hand, the Dow registered a gain of 0.53%, and the technology-centric Nasdaq increased by 0.4%.The the stock of medical device manufacturer has risen by 1.21% in the past month, leading the Medical sector's gain of 0.79% and undershooting the S&P 500's gain of 3.78%.Analysts and investors alike will be keeping a close eye on the p ...

MARLBOROUGH, Mass., July 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on Ju ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. CES, the world's largest annual consumer technology trade show, runs through January 12 and features about 4,000 exhibitors showing off their latest products and services to more than 130,000 attendees. (Photo by Ethan Miller/Getty Images)Getty ImagesAbbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its pe ...

文章核心观点 - 公司股价在最新交易中小幅上涨0.01%,表现优于同期S&P 500指数下跌0.41% [1] - 公司过去一个月股价上涨2.67%,领先医疗行业1.74%的涨幅,但低于S&P 500指数3.53%的涨幅 [2] - 公司即将公布的季度财报预计每股收益将同比增长9.43%,收入同比增长11.68% [3] - 全年来看,公司每股收益和收入预计将分别同比增长13.17%和12.3% [4] 公司相关 - 分析师对公司业务表现和盈利能力持乐观态度,上调了公司业绩预测 [5][6] - 公司当前的Zacks评级为3级(持有) [7] - 公司估值方面,其市盈率高于行业平均水平,PEG率也高于行业平均 [8][9] 行业相关 - 公司所属的医疗器械行业目前在250多个行业中排名靠后,位于底部41% [10][11] - 历史数据显示,排名靠前的行业整体表现优于排名靠后的行业 [11]

Boston Scientific, Inc. (BSX) recently obtained a CE Mark on the Vercise Neural Navigator 5 Software with STIMVIEW XT technology. When used as an element of the Vercise Genus Deep Brain Stimulation (DBS) Systems, it can provide clinicians with simple and actionable data for efficient programming to treat Parkinson’s disease, essential tremor and dystonia.The latest development comes as a significant boost for the company’s Neuromodulation business. In July 2023, the software had received the FDA’s approval. ...

文章核心观点 - 美国股市在6月创下历史新高,主要指数连续创出新高 [1] - 人工智能(AI)相关股票如英伟达、微软和苹果等市值最高的公司表现强劲 [2] - 交易者的看涨押注创下历史新高,尤其是那些今年表现最佳的大型科技股 [3][4] 根据相关目录分别进行总结 新兴公司表现亮眼 - 家庭安全应用Life360(LIF)上市后股价稳步上涨,目前每股31.21美元 [6] - 分析师对Life360给予积极评级,11家分析师给予买入评级,平均目标价为52.07美元,较当前价格上涨67% [7] - Life360拥有6600万活跃用户,新上市公司表现强劲 [9] 医疗行业龙头表现稳健 - 波士顿科学(BSX)是医疗器械行业知名企业,开发了广泛应用的Taxus支架 [10] - 由于心脏病是美国主要死因,波士顿科学预计将持续增长 [11] - 波士顿科学最近收购了Silk Road Medical,股价创新高,市盈率达65.3倍 [12] - 分析师预计波士顿科学未来仍有上涨空间,目标价82.93美元,较当前价格上涨6.7% [13] 安全认证公司前景看好 - 科雷恩NXT(CXT)提供微光学安全产品和货币防伪解决方案 [14] - 公司最近收购OpSec Security以增强在线保护和产品认证业务 [15] - 公司任命新的支付业务负责人,该业务占总收入的三分之二,股价创新高 [16] - 尽管今年已涨14%,但CXT股票市盈率仅20倍,与同行业相当 [17] - 分析师给予强烈买入评级,目标价98.20美元,较当前价格上涨52% [18]

In the latest trading session, Boston Scientific (BSX) closed at $76.71, marking a -1.29% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.31% for the day. Elsewhere, the Dow saw an upswing of 0.67%, while the tech-heavy Nasdaq depreciated by 1.09%.Shares of the medical device manufacturer witnessed a gain of 2.75% over the previous month, beating the performance of the Medical sector with its gain of 0.61% and the S&P 500's gain of 2.73%.Analysts and investors a ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Boston Scientific current ...

Boston Scientific (BSX) has announced plans to acquire carotid artery device specialist Silk Road Medical for approximately $1.26 billion. This is a strategic move poised to significantly expand the company’s cardiology portfolio.By paying $27.50 per share, Boston Scientific is offering a 38% premium over Silk Road's volume-weighted average share price over the past 60 days. With this transaction, expected to close in the second half of 2024, Silk Road will become a wholly owned subsidiary of the MedTech gi ...

The Zacks Medical – Products industry’s revenues are expected to continue its growth trajectory on the back of the recovery in demand for surgeries and procedures, new products and expansion into new markets. An earlier-than-expected demand for respiratory products is also boosting sales. The industry players are raising prices of their products and services to cope with the higher costs, thereby benefiting the top and bottom lines. However, the company continues to face challenges due to supply-chain const ...